Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 1609 • ACR Convergence 2025
A Multicenter Prospective Longitudinal Observational Study To Determine Safety Of Extended Treatment With Rituximab In Maintaining Remission In Patients With ANCA Associated Vasculitis (AAV) – An Interim Analysis
Ravi Kumar U¹, Anoop Chitrabhanu², Ramya Janardana³, Avinash Jain⁴, Nitty Mathews⁵, Rutvi Dave⁵, Prabhu Vasantha Kumar⁶, ashish mathew⁵, john mathew⁵, Prasanna Samuel⁵, Arul Rajamurugan², Vineeta Shobha³ and ruchika goel⁵, ¹Christian Medical college, Vellore, India, Bengaluru, Karnataka, India, ²Madras Medical College, Chennai, India, Chennai, Tamil Nadu, India, ³St. John’s Medical College, Bengaluru , India, Bangalore, Karnataka, India, ⁴SMS Medical College and Hospital, Jaipur, India, JAIPUR, Rajasthan, India, ⁵Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ⁶Christian Medical College, Vellore, Tamil Nadu, India, Vellore, Tamil Nadu, India
Background/Purpose: Rituximab (RTX) has been shown to achieve high remission-induction and sustained maintenance rates across multiple studies and clinical trials in patients with AAV. The…
Abstract Number: 1592 • ACR Convergence 2025
Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Adrien Cottu¹, Irene Mattioli², Xavier Puéchal³, Loic Guillevin⁴, Mathieu Groh⁵, Camille Taillé⁶, Maxime Samson⁷, Pascal Cathébras⁸, Halil Yildiz⁹, Grégory Pugnet¹⁰, Stéphane Jouneau¹¹, Marie-Charlotte Besse¹², François Lifermann¹³, Jean-Philippe Martellosio¹⁴, Laurent Guilleminault¹⁵, Colas Tcherakian¹⁶, Yann Nguyen¹⁷, Claire Demoreuil¹⁸, Philippe Guilpain¹⁹, Giacomo Emmi²⁰ and Benjamin Terrier²¹, ¹Internal medicine departement, Cochin Hospital, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Hôpital Foch, Suresnes, France, ⁶Bichat hospital, APHP, Paris, France, ⁷CHU Dijon Bourgogne, Dijon, France, ⁸Internal medicine department, CHU St-Etienne, Saint-Etienne, France, ⁹Internal medicine department, Saint-Luc, Saint-Luc, France, ¹⁰CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ¹¹Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ¹²Tours University Hospital, ³⁷⁰⁰⁰ tours, Ile-de-France, France, ¹³Internal Medicine, CH de Dax, Dax, France, ¹⁴Internal medicine department, CHU Poitiers, Poitiers, France, ¹⁵CHU Toulouse, Toulouse University, Toulouse, France, ¹⁶Pneumology department, Foch, Suresnes, France, ¹⁷Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁸Internal medicine department, Brest CHU, Brest, France, ¹⁹Internal medicine department, CHU Montpellier, Montpellier, France, ²⁰Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, Trieste, Italy, ²¹Cochin Hospital, Paris, France
Background/Purpose: Glucocorticoid (GC)-dependent asthma and ENT exacerbations may persist in more than half of patients with eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab and benralizumab, monoclonal…
Abstract Number: 0730 • ACR Convergence 2025
Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
Victor Pimentel-Quiroz¹, Alvaro Oyarce-Calderón², Allison Figueroa-Sánchez³, Leonor León-Yaurimucha³, Rocío Gamboa-Cárdenas⁴, Zoila Rodríguez-Bellido⁵, Risto Perich-Campos⁶, Graciela Alarcón⁷ and Manuel Ugarte-Gil⁸, ¹Universidad Científica del Sur, San Isidro, Peru, ²Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA, ⁸Universidad Cientifica del Sur, Lima, Peru
Background/Purpose: It is known that health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) is impaired. Categories of disease activity levels have been…
Abstract Number: 2506 • ACR Convergence 2025
Timing, Management, and Outcomes of Venous Thromboembolic Events in ANCA-Associated Vasculitis: A Retrospective Cohort Study
Bruno Marchetti¹, Michele Iudici², Yann Nguyen³, Pascal Cohen⁴, Loic Guillevin⁴, Xavier Puéchal⁵ and Benjamin Terrier⁶, ¹Department of Internal Medicine, University of Turin, Mauriziano Hospital, Torino, Italy, ²Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, ³Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁶Cochin Hospital, Paris, France
Background/Purpose: ANCA-associated vasculitis (AAV) has been associated with an increased risk of venous thromboembolic events (VTE). However, limited data are available regarding the precise timing,…
Abstract Number: 1608 • ACR Convergence 2025
Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Christian Pagnoux⁸, Ulrich Specks⁹, Benjamin Terrier¹⁰, Lena Börjesson Sjö¹¹, Priya Jain¹², Aadarsh Lal¹³, Sofia Necander¹⁴, Claire Walton¹⁵ and Michael Wechsler¹⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁹Mayo Clinic, Rochester, MN, ¹⁰Cochin Hospital, Paris, France, ¹¹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹³Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹⁴Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁵Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁶Department of Medicine, National Jewish Health, Denver
Background/Purpose: Results from the 1-year double-blind period and first year of the open-label extension (OLE) of the MANDARA trial (NCT04157348) demonstrated that over 60% of…
Abstract Number: 1277 • ACR Convergence 2025
Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
Eileen Rife¹, Daniel Reiff², John Bridges³, Emily Smitherman¹, randy Cron¹, Matthew Stoll¹, Melissa Mannion¹, Peter Weiser⁴ and Livie Timmerman⁵, ¹University of Alabama at Birmingham, birmingham, AL, ²Boys Town Hospital, Omaha, ³University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, ⁵University of Alabama at Birmingham, Gardendale, AL
Background/Purpose: Current practice guidelines recommend either rituximab (RTX) or cyclophosphamide (CYC) for treatment of organ-threatening manifestations of systemic vasculitis or connective tissue disease (e.g., diffuse…
Abstract Number: 0729 • ACR Convergence 2025
ANCA-associated vasculitis – does the type matter?
Tamanna Vinodkumar Mohta¹ and Umeh Chukwuemeka², ¹Hemet Global Medical Center, Irvine, CA, ²Hemet Global Medical Center, Hemet
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a heterogeneous group of rare autoimmune disorders that cause inflammation of blood vessels with various manifestations. Our study…
Abstract Number: 2507 • ACR Convergence 2025
Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)
Camille Mettler¹, Laurent Chouchana² and Benjamin Terrier³, ¹Département de Médecine interne, Hôpital Bichat-Claude-Bernard, Paris, France, ²Département de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Cochin, Paris, France, ³Cochin Hospital, Paris, France
Background/Purpose: Avacopan, an oral C5aR antagonist, is approved for the treatment of ANCA-associated vasculitis (AAV) as a steroid-sparing alternative. While clinical trials demonstrated a positive…
Abstract Number: 1607 • ACR Convergence 2025
Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
Natasha Le Blanc¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Nataliya Milman⁹, Medha Soowamber¹⁰, Nader Khalidi¹¹, Christian Pagnoux¹⁰, Rosalie-Selene Meunier¹², Jan Willem Cohen Tervaert⁴, Elaine Yacyshyn⁴ and Arielle Mendel¹³, ¹McGill University, Montreal, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Self employed, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Universite de Montreal, Montreal, Canada, ⁹the Ottawa Hospital, Ottawa, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Hopital du Sacre-Coeur-de-Montreal, Montreal, QC, Canada, ¹³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Antibiotic prophylaxis is recommended during initial treatment of ANCA-associated vasculitis (AAV). We assessed characteristics associated with prophylaxis within a Canadian multicenter AAV cohort starting…
Abstract Number: 1162 • ACR Convergence 2025
Antineutrophil cytoplasmic antibody-associated isolated interstitial lung disease
Javier Narváez¹, Pol Maymó-Paituvi², Vanesa Vicens Zygmunt³, Guadalupe Bermudo⁴, Martí Aguilar-Coll⁵, Montserrat Roig Kim², Laia De Daniel Bisbe², Joan Miquel Nolla² and Maria Molina-Molina⁴, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ³Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁵Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: There is increasing evidence of the association between interstitial lung disease (ILD) and ANCA positivity without other manifestations of systemic vasculitis. The prognosis of…
Abstract Number: 0728 • ACR Convergence 2025
Incidence and Clinical Characteristics of ANCA-Associated Vasculitis: A Nationwide Study in Spain
Susana Romero-Yuste¹, Marta Domínguez-Álvaro², Antonio Fernández-Nebro³, Miquel Blasco⁴, Beatriz Ventosa⁵, Javier Narváez⁶, Gema Fernández⁷, Iñigo Rúa-Figueroa⁸, Desirée Luis-Rodríguez⁹ and Manuel Macía¹⁰, ¹University Hospital Complex of Pontevedra, Pontevedra, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ⁴Hospital clinic Barcelona, Barcelona Spain, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital la Paz, Madrid, Madrid, Spain, ⁸Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁹Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain, ¹⁰Hospital Universitario Nuestra Señora de Candelaria,, Tenerife, Spain
Background/Purpose: ANCA-associated vasculitides (AAV)—granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis (MPA)are rare but severe systemic vasculitides with significant morbidity and…
Abstract Number: 2526 • ACR Convergence 2025
Infection Risk Associated with Steroid-Sparing Therapies in GCA, PMR, and ANCA-Associated Vasculitis: A Systematic Review
Divya Sudireddy¹, Brent Leung², Jean Liew³, Tuhina Neogi⁴, David Felson³, Michael LaValley⁵ and David Flynn², ¹Boston Medical Center, Westborough, MA, ²Boston University, Boston, ³Boston University, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Boston University School of Public Health, Arlington, MA
Background/Purpose: Giant cell arteritis (GCA), polymyalgia rheumatica (PMR), and ANCA-associated vasculitis (AAV) often require long-term glucocorticoid (GC) therapy, increasing the risk of infections, particularly in…
Abstract Number: 2505 • ACR Convergence 2025
Avacopan is Not Associated With An Increased Risk of Infection Compared to Glucocorticoids in Patients with ANCA-Associated Vasculitis
BEATRIZ MARIA FRANCO HONDERMANN, LOYOLA UNIVERSITY MEDICAL CENTER, OAK PARK
Background/Purpose: Avacopan is a novel C5a receptor inhibitor recently approved for treatment of ANCA-associated vasculitis as an alternative to glucocorticoids, It has demonstrated superior efficacy…
Abstract Number: 1606 • ACR Convergence 2025
One Year Real-World Effectiveness with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Large Healthcare System
Naomi Patel¹, Andrew King², Madison Negron³, Zachary Williams⁴, Ana Fernandes¹, Nora Shepherd², Colebrooke Johnson¹, Guy Katz¹, Belen Arevalo Molina¹, Elizabeth Ibiloye⁵, Sam Oh⁶, Zachary Wallace⁷ and Sebastian H Unizony⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Harvard Extension School, Medford, MA, ⁴Massachusetts General Hospital, Nancy, KY, ⁵Amgen Inc, Thousand Oaks, CA, ⁶Amgen Inc, South San Francisco, CA, ⁷Massachusetts General Hospital, Newton, MA, ⁸Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Avacopan has been approved for adjunctive use in adults with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the US. Here…
Abstract Number: 0900 • ACR Convergence 2025
Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis
Charlotta Preger¹, Maria Aspenberg¹, Metta Berenpas¹, Armita Dwivedi², Juliana Bordignon Draibe³, Peter Nilsson¹, Mark A. Little² and Elisa Pin¹, ¹Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, ²Trinity Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland, ³Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
Background/Purpose: ANCA-associated vasculitides (AAV) are a heterogenous group systemic autoimmune diseases characterized by necrotizing inflammation of small blood vessels requiring prompt initiation of immunosuppressive treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].